Search Within

Elizabeth F Halton

  1. "Advanced Practice Providers"
Formats
  1. Meeting Abstract (39)
  2. Journal Article (13)
  3. Research Letter (1)
Groups
  1. Advanced Practice Providers (53)
  2. Nursing (53)
  3. Department of Medicine (51)
  4. Center for Hematologic Malignancies (50)
  5. Hematologic Malignancies, Division of (50)
  6. Adult Leukemia (49)

More Groups

People
  1. Renier Brentjens (48)
  2. Jae Park (42)
  3. Isabelle Riviere (33)
  4. Claudia Diamonte (32)
  5. Michel Sadelain (28)
  6. Xiuyan Wang (24)

More People

Years
  1. 2022 (1)
  2. 2021 (7)
  3. 2020 (7)
  4. 2019 (12)
  5. 2018 (8)
  6. 2017 (7)

More Years

Publications
  1. Blood (18)
  2. Journal of Clinical Oncology (8)
  3. Biology of Blood and Marrow Transplantation (4)
  4. Blood Advances (3)
  5. Molecular Therapy (3)
  6. Cancer Discovery (2)

More Publications

Publishers
  1. American Society of Hematology (21)
  2. American Society of Clinical Oncology (8)
  3. Elsevier Inc. (6)
  4. Nature Publishing Group (6)
  5. American Association for Cancer Research (3)
  6. Oncology Nursing Society (ONS) (2)

More Publishers

Results (53)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Thirty day resource utilization after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies
    Meeting Abstract

    Shah, G. L.; Park, J.; Sauter, C. S.; Duck, E.; Halton, E.; Batlevi, C. W.; Palomba, M. L.; Younes, A.; Geyer, M. B.; Smith, E.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult ALL
    Meeting Abstract

    Perica, K.; Flynn, J.; Curran, K. J.; Wang, X.; Halton, E.; Diamonte, C.; Pineda, J.; Bernal, Y.; Gonen, M.; Riviere, I.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent
    Meeting Abstract

    Adusumilli, P. S.; Zauderer, M. G.; Rusch, V. W.; O'Cearbhaill, R.; Zhu, A.; Ngai, D.; McGee, E.; Chintala, N.; Messinger, J.; Cheema, W.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy
    Meeting Abstract

    Adusumilli, P. S.; Zauderer, M. G.; Rusch, V. W.; O'Cearbhaill, R. E.; Zhu, A.; Ngai, D. A.; McGee, E.; Chintala, N. K.; Messinger, J. C.; Vincent, A.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Resource utilization within 30 days of car T cells for hematologic malignancies
    Meeting Abstract

    Shah, G.; Park, J.; Sauter, C.; Duck, E.; Halton, E.; Batlevi, C.; Palomba, M. L.; Younes, A.; Geyer, M.; Smith, E.; more...
    Value in Health (2019)

    Fulltext@MSK | Save
  • Phase I clinical trial of CD19‐targeted 19‐28z/4‐1BBL "armored" CAR T cells in patients with relapsed or refractory NHL and CLL including Richter transformation
    Meeting Abstract

    Batlevi, C. L.; Palomba, M. L.; Park, J.; Mead, E.; Santomasso, B.; Riviere, I.; Wang, X.; Senechal, B.; Furman, R.; Yang, J.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL
    Journal Article

    Geyer, M. B.; Riviere, I.; Senechal, B.; Wang, X.; Wang, Y.; Purdon, T. J.; Hsu, M.; Devlin, S. M.; Palomba, M. L.; Halton, E.; more...
    JCI Insight (2019)

    Fulltext@MSK | Save
  • Resource utilization early after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies
    Meeting Abstract

    Shah, G. L.; Park, J. H.; Sauter, C. S.; Duck, E.; Halton, E.; Palomba, M. L.; Batlevi, C. L.; Younes, A.; Geyer, M. B.; Smith, E. L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • A phase I first-in-human clinical trial of CD19-targeted 19-28z/4-1BBL "armored" CAR T cells in patients with relapsed or refractory NHL and CLL including Richter's transformation
    Meeting Abstract

    Park, J. H.; Palomba, M. L.; Batlevi, C. L.; Riviere, I.; Wang, X.; Senechal, B.; Furman, R. R.; Bernal, Y.; Hall, M.; Pineda, J.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Clinical responses and pharmacokinetics of MCARH171, a human-derived BCMA targeted CAR T cell therapy in relapsed/refractory multiple myeloma: Final results of a phase I clinical trial
    Meeting Abstract

    Mailankody, S.; Ghosh, A.; Staehr, M.; Purdon, T. J.; Roshal, M.; Halton, E.; Diamonte, C.; Pineda, J.; Anant, P.; Bernal, Y.; more...
    Blood (2018)

    Fulltext@MSK | Save